fashion -WSS

fashion

author：fashion 2025-10-03 00:22:11 - browse：39

The Food and Drug Administration on Friday approved a new, rapid-acting medicine made by Sage Therapeutics to treat postpartum depression, the first oral treatment for the condition. But the agency denied the company’s application for an indication for major depression, a much larger potential market.

The drug, which will be sold under the brand name Zurzuvae, is not meant to be taken chronically. Patients take it orally for 14 days. In two clinical trials, the drug was found to significantly improve depressive symptoms more than a placebo. The effect was maintained for four weeks after treatment.

“Maternal mental health has been sidelined for far too long, but today’s approval of Zurzuvae helps to change that. Women have been waiting for an oral medicine that can specifically and rapidly improve the symptoms of PPD and we are proud to be able to deliver that,” said Barry Greene, Sage’s CEO, in a press release.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

WSS

How digital tools helped lower hypertension in marginalized patients

JPM: CVS says Medicare Advantage patients are impacting profits

Ahead of JPM, here's who's profiting most in health care

Industry veterans launch new biotech VC with $310M

Robert F. Kennedy is pitching centrism on health, even on abortion

For Medicare Advantage, Democrats want stronger protections around AI

knowledge

fashion

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Gilead might be held responsible for not developing a drug

Affirmative action in medical school literally saved lives

What should King Charles tell the public about his cancer?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

U.K. sequencing study surfaces new findings about tumor DNA

Duchenne breakthrough therapy leaves behind pioneering families

Medicare Advantage proposed rates disappoint insurers

Continuity nursing helped my family in our darkest PICU moments

How digital tools helped lower hypertension in marginalized patients

Wikipedia

PhRMA lawsuit over Medicare drug price negotiation tossed

Industry veterans launch new biotech VC with $310M

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

3 medical device trends to watch in 2024

Antibiotic resistance and the global rise in human conflict

For Medicare Advantage, Democrats want stronger protections around AI

knowledge

explore

hotspot

focus